Press Releases

03/24/2021

Clinical Trials

FDA Grants Breakthrough Device Designation To Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atr...

03/15/2021

Community Health Network Collaborates with Tempus to Personalize Cancer Care, Improve Patient Health Through Genomics Testing

Community Health Network announced today it is collaborating with Tempus, a leader in precision medicine and artificial intelligence, to improve patient health and outcomes through genomic testing. Among a variety of precision medicine solutions, Tempus offers a suite of oncology-focused genomic testing and targeted clinical trial matching. The...

03/05/2021

Researchers Find AI Can Predict New Atrial Fibrillation, Stroke Risk

A team of scientists from Geisinger and Tempus have found that artificial intelligence can predict risk of new atrial fibrillation (AF) and AF-related stroke. Atrial fibrillation is the most common cardiac arrhythmia and is associated with numerous health risks, including stroke and death. The study, published in Circulation, used el...

02/25/2021

Tempus Announces Sequencing and Computational Biology Collaboration with Kronos Bio to Support the Development of CDK9 Inhibitor KB-0742

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Tempus will use its xT broad-panel genomic assay to provide retrospective sequenc...

02/23/2021

Genomic Sequencing

Tempus and Precision Health Informatics Announce Precision Medicine Collaboration

Tempus, a leader in precision medicine and artificial intelligence, today announced its collaboration with Precision Health Informatics, a wholly-owned subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine in oncology. This collaboration aims to further precision medicine research through unique insights derived from Pre...

02/11/2021

Tempus Announces the Appointment of Nobel Laureate and CRISPR Co-Inventor, Dr. Jennifer Doudna, to its Board of Directors

Tempus, a leader in artificial intelligence and precision medicine, today announced that Dr. Jennifer Doudna has joined its Board of Directors. Dr. Doudna will serve as an advisor to Tempus and its leadership team, leveraging her vast experience in genomics innovation and research to support Tempus as it leads the way in ap...

02/09/2021

Tempus Launches Hereditary Cancer Germline Assay, xG

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its new germline sequencing assay, xG, a 52-gene panel that specifically identifies genetic variants associated with hereditary cancer syndromes and inherited risk of cancer. Tempus xG, which is now available to order, is performed by GeneDx, I...

01/27/2021

Tempus Expands Licensing Agreement with Bristol Myers Squibb to Analyze and Discover RNA-Based Targets

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to n...

01/22/2021

Clinical Breast Cancer Study Reveals that Tempus’ Real-World Database Mirrors Overall U.S. Breast Cancer Population

Tempus, a leader in artificial intelligence and precision medicine, announces a recent study in Clinical Breast Cancer that demonstrates how Tempus’ real-world database mirrors the U.S. breast cancer population, ultimately suggesting that real-time, real-world data analyses are feasible in a large, highly heterogeneous database. For the study,...

01/13/2021

Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the...

NEWS

Media Coverage

Additional Partnerships